THYROID CANCERS

AIC100 now has a regenerative medicine advanced therapy designation from the FDA for the treatment of recurrent anaplastic thyroid cancer.

Francis P. Worden, MD, discusses future plans to investigate combination therapies and other novel treatments in the thyroid cancer space.

In an interview with Targeted Oncology, Francis P. Worden, MD, delved into the rationale behind the study and the implications of this research for patients with radioidine-refractory differentiated thyroid cancer.

During a Case-Based Roundtable® event, Lori J. Wirth, MD, discussed with participants how they approach use of lenvatinib and other therapy for patients with radioactive iodine–refractory differentiated thyroid cancer.

Francis P. Worden, MD, provides a brief overview of the approval of selpercatinib and what it means for patients with RET fusion-positive thyroid cancer.

Cesar Augusto Perez, MD, discusses one of the top unmet needs that exists in the thyroid cancer space.

Lori J. Wirth, MD, offers advice to oncologists using lenvatinib when treating patients with differentiated thyroid cancer.

The approval of selpercatinib marks the first targeted therapy for pediatric patients with RET gene alterations in solid and thyroid tumors.

In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, MBA, FACP, FCCP, discussed the role of larotrectinib in a patient with NTRK fusion–positive cancer.

A novel scoring system including radiomics data may help clinicians identify the risk of central lymph node metastasis in patients with a subtype of thyroid cancer.

Lova Sun, MD, MCSE, discussed genetic mutations in thyroid cancer and how they impact clinicians’ treatment options.

Lori J. Wirth, MD, discusses the outcomes of treatment with larotrectinib for patients with NTRK fusion–positive advanced thyroid cancer.

Lova Sun, MD, discusses genetic alterations in thyroid cancer, including RET and NTRK alterations, and how these can affect treatment options.

Lori J. Wirth, MD, discussed advancements in diagnosing and treating thyroid cancer, offering community oncologists improved tools for identifying low-risk cancers, personalizing treatment, and exploring innovative approaches.

Lori J. Wirth, MD, discusses imaging techniques, biomarker identification, and promising treatments on the horizon in the thyroid cancer space.

Marcia S. Brose, MD, PhD, FASCO, discusses potential next steps for approaching and treating patients with advanced or metastatic RET-mutant thyroid cancer.

Lori J. Wirth, MD, provides an overview on the latest advancements in diagnosis of thyroid cancer.

Whole-exome sequencing identified genetic mutations associated with poorly differentiated thyroid cancer, paving a new path for research in the field.

Francis P. Worden, MD, reviews the progression-free survival data and safety findings from the phase 3 COSMIC-311 study which evaluated treatment with cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer.

Marcia S. Brose, MD, PhD, FASCO, discusses her hopes for the future of selpercatinib in treating advanced or metastatic RET-mutant thyroid cancer.

Marcia S. Brose, MD, PhD, discusses treatment sequencing practices and offers advice for community oncologists treating patients with RAI-R-DTC.

Focusing on lenvatinib, an expert on RAI-R-DTC discusses data on real-world treatment patterns and clinical outcomes and gives an overview of papers on age and dose.

Marcia S. Brose, MD, PhD, discusses her experience with lenvatinib as a treatment for patients with RAI-R-DTC.